Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2

Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2

Abstract Introduction Guselkumab is a human monoclonal antibody against IL-23 used in the treatment of moderate-to-severe psoriasis. This post-hoc analysis evaluated the efficacy and safety of guselkumab in the Asian subpopulation of VOYAGE 1 and VOYAGE 2 through 5 years. Methods The proportions of...

Full description

Bibliographic Details
Main Authors: Byung Soo Kim, Seong Jin Jo, SangWoong Youn, Kristian Reich, Carine Saadoun, Chia-Ling Chang, Ya-Wen Yang, Yu-Huei Huang, Tsen-Fang Tsai
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-09-01
Series:Dermatology and Therapy
Subjects:
Asian
Biologics
Guselkumab
Moderate-to-severe
Psoriasis
Online Access:https://doi.org/10.1007/s13555-023-01026-7

Internet

https://doi.org/10.1007/s13555-023-01026-7

Similar Items